Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Down 32.3% in March

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a large decrease in short interest in March. As of March 13th, there was short interest totaling 1,402,079 shares, a decrease of 32.3% from the February 26th total of 2,069,809 shares. Currently, 3.8% of the company’s shares are short sold. Based on an average trading volume of 497,946 shares, the days-to-cover ratio is currently 2.8 days.

Insiders Place Their Bets

In other Werewolf Therapeutics news, Director Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $0.61, for a total transaction of $66,249.66. Following the transaction, the director directly owned 2,550,674 shares in the company, valued at approximately $1,555,911.14. The trade was a 4.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 499,420 shares of company stock worth $296,825. Insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics during the first quarter valued at approximately $79,000. Quadrature Capital Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter worth $28,000. Marshall Wace LLP bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $113,000. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter worth $48,000. Finally, Jane Street Group LLC bought a new position in Werewolf Therapeutics in the 2nd quarter worth $409,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Down 9.5%

NASDAQ:HOWL traded down $0.08 during mid-day trading on Friday, reaching $0.78. The stock had a trading volume of 374,982 shares, compared to its average volume of 381,100. The stock has a market cap of $37.90 million, a P/E ratio of -0.57 and a beta of 0.78. The business’s 50 day moving average is $0.69 and its 200 day moving average is $1.03. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Tuesday, March 31st. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.15. As a group, sell-side analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on HOWL shares. HC Wainwright decreased their price objective on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, January 21st. Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Wedbush cut shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target for the company. in a report on Friday, December 19th. Finally, Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Werewolf Therapeutics has an average rating of “Hold” and a consensus price target of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.